BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Investor Presentation
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Balaxi Pharmaceuticals filed an investor presentation detailing its Q1 FY26 results. Revenue grew 8% year-on-year to ₹70.74 crore, supported by stable demand across its African and Latin American markets. Gross margin improved to 44% from 41.9% in the year-ago quarter, reflecting the strength of its branded generic business. However, profit after tax fell sharply to ₹3.29 lakhs compared to ₹6.48 crore in Q1 FY25, hurt by one-time administrative write-offs and losses from its newly subsidiarized Nicaragua operations. The company secured 14 new product registrations, bringing the total to 929, and confirmed that its first pharmaceutical formulation plant in Hyderabad has completed installation, operational, and performance qualification, with commercial stability batches expected to begin in early September 2025.
The sharp drop in bottom-line profit despite revenue and gross margin gains is a negative near-term signal, though the new manufacturing facility and expanding product portfolio point to longer-term growth potential once commercial production begins.